Results 81 to 90 of about 2,198 (193)

Research Progress on RET Fusion in Non-Small-Cell Lung Cancer

Frontiers in Oncology, 2022
Great progress has been made in the treatment of driver gene-positive Non- Small Cell Lung Cancer (NSCLC) in recent years. RET fusion was seen in 0.7% to 2% of NSCLC and was associated with younger age and never-smoker status.
Lu Zhao, Lu Zhao, Qingyun Mei, Qingyun Mei, Yongchao Yu, Yongchao Yu, Na Wang, Na Wang, Dou Zhang, Dou Zhang, Dongying Liao, Dongying Liao, Jinhui Zuo, Jinhui Zuo, Hongxia Xie, Hongxia Xie, Yingjie Jia, Yingjie Jia, Fanming Kong, Fanming Kong   +19 more
doaj   +1 more source

Durable Response to Combined Osimertinib and Pralsetinib Treatment for Osimertinib Resistance Due to Novel IntergenicANK3-RETFusion inEGFR-Mutated Non–Small-Cell Lung Cancer [PDF]

, 2022
Edyta Maria Urbanska, Jens Benn Sørensen, Linea Cecilie Melchior, Junia C. Costa, Eric Santoni‐Rugiu   +4 more
openalex   +1 more source

Personalized care for patients with EGFR‐mutant nonsmall cell lung cancer: Navigating early to advanced disease management

CA: A Cancer Journal for Clinicians, Volume 75, Issue 5, Page 387-409, September/October 2025.
Abstract The discovery of activating mutations in the epidermal growth factor receptor (EGFR) gene has revolutionized the management of lung cancer, enabling the development of targeted tyrosine kinase inhibitors (TKIs). These therapies offer improved survival and reduced side effects compared with conventional treatments.
Maxime Borgeaud, Timothée Olivier, Jair Bar, Stephanie Pei Li Saw, Kaushal Parikh, Giuseppe Luigi Banna, Claudio De Vito, Jill Feldman, Xiuning Le, Alfredo Addeo   +9 more
wiley   +1 more source

RET rearrangement as a mechanism of resistance to ALK-TKI in non-small cell lung cancer patient with EML4-ALK fusion: A case report

Heliyon
Patients with non-small cell lung cancer (NSCLC) and anaplastic lymphoma kinase (ALK) mutations have previously derived substantial benefits from ALK tyrosine kinase inhibitors (ALK-TKIs). However, resistance may develop in some patients.
Huan Yan, Liang Zeng, Yongchang Zhang
doaj   +1 more source

Oncogenic gene fusions in cancer: from biology to therapy. [PDF]

Oncogenic gene fusions occur across a broad range of cancers and are a defining feature of some cancer types. Cancers driven by gene fusion products tend to respond well to targeted therapies, where available; thus, detection of potentially targetable ...
Atz, Judith, Liu, Stephen, Müllauer, Leonhard, Nagasaka, Misako, Solca, Flavio   +4 more
core   +1 more source

Review Article: New Treatments for Advanced Differentiated Thyroid Cancers and Potential Mechanisms of Drug Resistance [PDF]

, 2023
The treatment of advanced, radioiodine refractory, differentiated thyroid cancers (RR-DTCs) has undergone major advancements in the last decade, causing a paradigm shift in the management and prognosis of these patients.
Busaidy, Naifa L, Cabanillas, Maria E, Dadu, Ramona, Hamidi, Sarah, Hofmann, Marie-Claude, Hu, Mimi I, Iyer, Priyanka C   +6 more
core   +1 more source

Therapeutic strategies in RET gene rearranged non-small cell lung cancer

Journal of Hematology & Oncology, 2021
The recent approvals by the Food and Drug Administration several tumor-agnostic drugs have resulted in a paradigm shift in cancer treatment from an organ/histology-specific strategy to biomarker-guided approaches.
Leylah M. Drusbosky, Estelamari Rodriguez, Richa Dawar, Chukwuemeka V. Ikpeazu   +3 more
doaj   +1 more source

Common miRNAs, Genes, and Regulatory Pathways in Alzheimer's Disease and Type 2 Diabetes Mellitus: An Integrative Analysis of Systematic Reviews, Bioinformatics and Data Mining

Journal of Neurochemistry, Volume 169, Issue 8, August 2025.
Alzheimer's disease (AD) and type 2 diabetes mellitus (T2DM) are frequent conditions affecting older adults, with evidence suggesting a higher predisposition for AD in diabetic patients. MicroRNAs (miRNAs) are proposed as regulators of gene expression in the mutual pathways among these diseases. In this study, the T‐cell receptor–RAS signaling (TCR‐RAS)
Lívia Cristina Ribeiro Teixeira, Jessica Diniz Pereira, Izabela Mamede, Paulo Caramelli, Vítor Corrêa Silva, Adriano Alonso Veloso, Marcelo Rizzatti Luizon, Karina Braga Gomes   +7 more
wiley   +1 more source

Cancer drug applications to the EMA and the FDA: A comparison of new drugs and extension of indication in terms of approval decisions and time in review

British Journal of Clinical Pharmacology, Volume 91, Issue 5, Page 1431-1438, May 2025.
Abstract Aims The aim of this study was to compare the final approval decision and time from submission to final decision for new drug applications and applications for extension of indications to the EMA and the FDA within cancer drugs. Methods We performed a retrospective analysis on antineoplastic drug applications with a final decision in both the ...
Allan Cramer, Freja Karuna Hemmingsen Sørup, Hanne Rolighed Christensen, Tonny Studsgaard Petersen, Kristian Karstoft   +4 more
wiley   +1 more source

Addressing challenges with real-world synthetic control arms to demonstrate the comparative effectiveness of Pralsetinib in non-small cell lung cancer

Nature Communications, 2022
Real-world data (RWD) based control arms provide an option to compare the effectiveness of single-arm trials. By performing multiple quantitative bias analyses to alleviate concerns about trial-RWD comparability, here the authors show that the RET ...
Sanjay Popat, Stephen V. Liu, Nicolas Scheuer, Grace G. Hsu, Alexandre Lockhart, Sreeram V. Ramagopalan, Frank Griesinger, Vivek Subbiah   +7 more
doaj   +1 more source